Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism

PHASE3RecruitingINTERVENTIONAL

Enrollment

424

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

November 26, 2026

Study Completion Date

November 26, 2026

Conditions

Secondary Hyperparathyroidism, Chronic Kidney Disease

Interventions

DRUG

MT1013

MT1013 + dummy cinacalcet

DRUG

Cinacalcet

Cinacalcet + dummy MT1013

Trial Locations (1)

RECRUITING

Zhongshan Hospital, Shanghai

All Listed Sponsors

lead

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

INDUSTRY